Immunopathology of galectin-3: an increasingly promising target in COVID-19

John L. Caniglia(University of Illinois Urbana-Champaign), Kiran Kumar Velpula(Illinois College), Swapna Asuthkar(University of Illinois Urbana-Champaign), Andrew J. Tsung(Illinois College), Maheedhara R. Guda(University of Illinois Urbana-Champaign)
F1000Research
September 28, 2020
10.12688/f1000research.25979.2
Cited by 77

Related Papers

B7-H3 role in the immune landscape of cancer.
|PubMed|2017|175
An overview of MCT1 and MCT4 in GBM: small molecule transporters with large implications.
|PubMed|2018|106
Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment.
|PubMed|2016|98
A potential role for Galectin-3 inhibitors in the treatment of COVID-19
|PeerJ|2020|90
Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept
|CNS Oncology|2016|81